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This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in
pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an infection
and receiving systemic antibiotic therapy. Patients were enrolled into four age cohorts (cohort 1,>12 to<18 years; cohort 2,>6
to<12 years; cohort 3,>2 to<6 years; cohort 4,>3 months to<2 years). Patients received a single 2-h intravenous infusion of
ceftazidime-avibactam (cohort 1, 2,000 to 500 mg; cohort 2, 2,000 to 500 mg [>40 kg] or 50 to 12.5 mg/kg [<40 kg]; cohorts 3
and 4, 50 to 12.5 mg/kg). Blood samples were collected to describe individual PK characteristics for ceftazidime and avibactam.
Population PKmodeling was used to describe characteristics of ceftazidime and avibactam PK across all age groups. Safety and
tolerability were assessed. Thirty-two patients received study drug. Mean plasma concentration-time curves, geometric mean
maximum concentration (Cmax), and area under the concentration-time curve from time zero to infinity (AUC0–) were similar
across all cohorts for both drugs. Six patients (18.8%) reported an adverse event, all mild or moderate in intensity. No deaths or
serious adverse events occurred. The single-dose PK of ceftazidime and avibactam were comparable between each of the 4 age
cohorts investigated and were broadly similar to those previously observed in adults. No new safety concerns were identified.
(This study has been registered at ClinicalTrials.gov under registration no. NCT01893346.)
In recent years there has been a global increase in the prevalenceof multidrug-resistant Gram-negative pathogens in adults and
children, including extended-spectrum -lactamase and carbap-
enemase-producing Enterobacteriaceae. Longstanding carbap-
enem resistance has been documented in Pseudomonas aeruginosa
since the approval and use of the first carbapenem, imipenem-
cilastatin (1–5). There have also been reports of an increasing
trend toward antibiotic resistance among Enterobacteriaceae iso-
lated from children (6, 7). As a consequence of increasing resis-
tance, the utility of many antibiotic classes (including the cepha-
losporins and carbapenems) to treat serious Gram-negative
infections has become compromised (8–12), creating an urgent
need for new antibiotic therapies that utilize novel mechanisms of
action. In particular, very few options have been investigated for
the treatment of complicated Gram-negative infections in pediat-
ric patients, and although several novel agents are in clinical de-
velopment, pharmacokinetic (PK) data in children and adoles-
cents is limited at present (13).
The PK profile of drugs differs between pediatric and adult
patients (14). Body size and physiology develop rapidly in the first
few years of life, resulting in significant differences in the absorp-
tion, distribution, metabolism, and excretion of drugs between
pediatric and adult patients (15). Studies are required to assess the
PK, safety, and tolerability of newdrugs in all pediatric age groups.
Ceftazidime is an extended-spectrum antipseudomonal ceph-
alosporin that was first approved in 1985 for the treatment of
complicated infections in adults, with approval for children
shortly thereafter (16). Widespread -lactamase-mediated resis-
tance has greatly reduced cephalosporin effectiveness (17); there-
fore, the combination of ceftazidimewith avibactam, a novel non-
-lactam -lactamase inhibitor, represents an important new
option for the treatment of serious Gram-negative infections (18–
21). Avibactam has been shown in vitro to inactivate Ambler class
A and C (including Klebsiella pneumoniae carbapenemases) and
some class D-lactamases, which restores the bactericidal activity
of ceftazidime against otherwise ceftazidime-resistant pathogens
carrying these-lactamases. However, avibactam does not inhibit
metallo--lactamases (22).
Ceftazidime-avibactam (2,000 mg and 500 mg, respectively) is
approved for adults in the U.S. for the treatment of complicated
intra-abdominal infections (cIAI), when used in combination
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with metronidazole, and complicated urinary tract infections
(cUTI) with limited or no alternative treatment options (23). The
efficacy and tolerability of ceftazidime-avibactam in the treat-
ment of adults with cIAI and cUTI has been demonstrated in
three recently reported phase III studies (NCT01499290,
NCT01500239, and NCT01644643), none of which raised any
new safety concerns (24, 25).
The primary objective of the phase I study reported here was to
characterize the PK profile of a single dose of ceftazidime-avibac-
tam in hospitalized infants and children with the aim of providing
data to support future clinical studies of ceftazidime-avibactam in
pediatric patients. Safety and tolerability were evaluated as sec-
ondary objectives.
(These data were presented in part at the 55th Interscience
Conference onAntimicrobial Agents andChemotherapy, 17 to 21
September 2015, San Diego, California [26].)
MATERIALS AND METHODS
Study design. This was a phase I, multicenter, open-label, single-dose
study (sponsor protocol number D4280C00014; ClinicalTrials.gov iden-
tifier NCT01893346) conducted in pediatric patients who were hospital-
ized with infections in the U.S. between July 2013 and October 2014. This
was not a therapeutic study, and ceftazidime-avibactam was not used to
treat the infection for which the patient had been hospitalized. The study
was approved by the local Institutional Review Board of each of the inves-
tigators and was performed in accordance with the ethical principles that
have their origin in the Declaration of Helsinki. The study is consistent
with International Conference on Harmonization (ICH)/Good Clini-
cal Practice (GCP) and applicable regulatory requirements and the
AstraZeneca policy on bioethics.
Patients. Patients eligible for inclusion were hospitalized male or fe-
male children aged3 months to18 years who were receiving systemic
antibiotic therapy for the treatment of a suspected or confirmed infection
and who were expected to require hospitalization for at least 24 to 48 h.
Hospitalization was mandatory for the first 24 h after infusion of ceftazi-
dime-avibactam, with early discharge possible if the patient was able to
return to the hospital/clinic for assessments on day 3. Patients were re-
quired to have sufficient intravenous (i.v.) access (peripheral or central) to
receive the study drug and adequate access for PK sampling and to be
likely to survive the current illness for which they were hospitalized. Pre-
scribed antibiotics used to treat the patient’s infection were to be contin-
ued without alteration.
Female subjectswhohad reached reproductivematuritywere required
to have a negative serum -human chorionic gonadotropin test just prior
to study entry and agree not to attempt pregnancy from the time of
screening until 7 days after receipt of study drug. Key exclusion criteria
were a history of hypersensitivity reactions to carbapenems, cephalospo-
rins, penicillin, other -lactam antibiotics, or metronidazole; a past or
current history of epilepsy or seizure disorder (excluding childhood fe-
brile seizures); severe renal impairment (creatinine clearance [CrCL] of
30 ml/min/1.73 m2); pregnancy or breastfeeding; acute hepatitis in the
prior 6 months; a history of cirrhosis, acute hepatic failure, or acute de-
compensation of chronic hepatic failure; and any condition, such as septic
shock, burns, or cystic fibrosis, that would make patients unsuitable for
analysis of PK as the basis for dosing in proposed phase II treatment trials
for cIAI and cUTI in children. Those with body mass index (BMI) below
the 5th and above the 95th percentile based on age, height, and weight
(excluding children 2 years old) were also excluded. Any patient who
received ceftazidime within 12 h of study drug administration (24 h if
CrCL was 50 ml/min) was also excluded. Patients (if age appropriate)
provided assent to participate, and the parent or legal guardian for each
patient provided written informed consent prior to any study-specific
procedures.
Treatment. The study included 4 cohorts grouped according to regu-
latory guidance (FDA pediatric guidance 2014), and each comprised at
least 8 evaluable patients: cohort 1,12 to18 years; cohort 2,6 to12
years; cohort 3, 2 to 6 years; and cohort 4, 3 months to 2 years.
Cohort 4 excluded young infants born prior to 37 weeks of gestation.
Dose regimens used in the present study are summarized in Table 1.
All doses were administered as a 2-h continuous i.v. infusion tomaximize
the pharmacodynamic (PD) exposure for -lactam antibiotics (27), i.e.,
the time duringwhich non-protein-bound (or “free”) antibiotic is present
at the site of infection at concentrations that are above the MIC of the
pathogen (fTMIC) (28). Dosing in cohorts 1 and 2 was based on the
probability of target attainment (PTA) of at least 90%by achieving the ap-
propriate fTMIC exposure in children in each age group, using popu-
lation PKmodels of ceftazidime and avibactam that were developed from
phase I and phase II studies in adults (29) and incorporating pediatric-
specific changes in ceftazidime and avibactam PK according to allometric
scaling for body weight (29). Dosing in cohorts 3 and 4 was based on
updated population PK models of ceftazidime and avibactam using data
from the older pediatric age groups in cohorts 1 and 2 and taking into
account literature-reported maturation of renal function in children2
years (30). The PK/PD targets used to determine doses for this study were
based on those established in adults: ceftazidime free plasma concentra-
tions above the ceftazidime-avibactam MIC (fTMIC) of 8 mg/liter and
avibactam free plasma concentrations above the critical threshold con-
centration (fTCT) of 1 mg/liter, both for approximately 50% of the
dosing interval (27–29). The PK/PD target of 50% fTMIC is a well-
characterized target for cephalosporins (31, 32), and a MIC of 8 mg/liter
was selected for the ceftazidime target as it encompasses the MIC90s for
Enterobacteriaceae (33, 34) and P. aeruginosa (21, 33, 35–37). The avibac-
tam target was based on fTCT, as this has previously been shown to be
the PD index that most accurately predicts avibactam efficacy in vitro and
in vivo (38, 39). A conservative CT of 1 mg/ml was selected for the PK/PD
target to ensure adequate levels of -lactamase inhibition to restore cef-
tazidime activity against representative ceftazidime-resistant strains of
Enterobacteriaceae and P. aeruginosa (38, 39). The time above CT of 50%
for avibactam was derived from preclinical studies (38) and also matches
the ceftazidime target of 50% fTMIC, thus protecting ceftazidime activ-
ity during the period it ismost active.Doseswere selected to achieve a PTA
of at least 90%, with ceftazidime and avibactam exposures comparable
with those in adults receiving ceftazidime-avibactam at 2,000 mg/500 mg
every 8 h (q8h; the FDA-approved dose for adults based on phase III
clinical trials), although not exceeding 20% higher than the simulated
exposure (area under the concentration-time curve [AUC] and maxi-
mumplasma concentration [Cmax]) observed in adults (40, 41). Doses for
TABLE 1 Summary of dose regimen used in the study
Drug
Dose (all administered as a 2-h i.v. infusion) for cohort:
1
(12 yr to18 yr)
2
(6 yr to12 yr)
3
(2 yr to6 yr)
4
(3 mo to2 yr)40 kg 40 kg
Ceftazidime 2,000 mg 2,000 mg 50 mg/kg 50 mg/kg 50 mg/kg
Avibactam 500 mg 500 mg 12.5 mg/kg 12.5 mg/kg 12.5 mg/kg
Ceftazidime-Avibactam Pediatric Pharmacokinetics
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cohorts 1 and 2 were determined from adult data; doses were subse-
quently determined for cohorts 3 and 4 based on data from cohorts 1 and
2. The final analysis, based on data from all available cohorts, supported
the appropriateness of dose selection for each cohort during study imple-
mentation, with predicted PTA for the PK/PD target of 98% in cohort 1
and 94% to 98% for cohorts 2 to 4. Central clearance estimates for cefta-
zidime and avibactam in pediatric patients were estimated to be 26% and
30% greater, respectively, than for healthy adult volunteers. The PTAs for
pediatric patients were predicted to be higher than the projected PTA in
adult patients with normal renal function (90%), and the predicted expo-
sure in Cmax and AUC in pediatric subjects overall were within 30% of
adult cIAI patients with mild renal impairment (42). Recruitment to co-
horts 1 and 2 was conducted in parallel. All available data from cohorts 1
and 2 were reviewed by the safety review committee prior to proceeding
with cohort 3. All available safety, tolerability, and predicted exposure
data from cohort 3 were reviewed when making dosing decisions for co-
hort 4. Predicted exposures in cohort 3 and cohort 4 were also considered
in all dosing decisions. Patients weremonitored for 48 h following the end
of study drug infusion.
Assessments. (i) Pharmacokinetics.Blood samples (1ml in cohorts 1
and 2, 0.5 ml in cohorts 3 and 4) were obtained for PK analysis at defined
sampling times (end of infusion [EOI] 5min and 30min, 1.5 h, 3 h, 6 h,
10 h, and 22 h after EOI) for cohort 1 and specific sampling time windows
for cohorts 2 to 4 (cohort 2, EOI 5 min and 15 to 45 min, 1 to 2 h, 2 to
3 h, 4 to 6 h, and 11 to 13 h after EOI; cohorts 3 and 4, EOI 5 min and
15 to 45min, 2 to 3 h, and 4 to 6 h after EOI). A sparse sampling approach
was used in cohorts 3 and 4 to minimize blood sampling requirements in
these smaller patients.
Ceftazidime and avibactam plasma concentrations were determined
by Covance Laboratories Limited (Harrogate, United Kingdom) using
liquid chromatography with tandemmass spectrometry (LC-MS/MS) ac-
cording to a previously reported validated methodology following solid-
phase extraction (avibactam) or protein precipitation (ceftazidime) (43).
All samples were analyzed within the known stability periods for ceftazi-
dime and avibactam. The lower limit of quantification was 50 ng/ml for
ceftazidime and 10 ng/ml for avibactam.
Ceftazidime and avibactam concentration-time courses were used to
derive individual noncompartmental PK parameters for cohorts 1 and 2,
including Cmax, AUC from time zero to last observed concentration
(AUC0–t), AUC from time zero to infinity (AUC0–), elimination half-life
(t1/2), volume of distribution at steady state (Vss), and clearance (CL).Due
to sparse sampling in cohorts 3 and 4, ceftazidime and avibactam non-
compartmental PK parameters could not be derived without population
PK analysis. In these cohorts, plasma concentrations at the EOI were used
as a comparable measurement for Cmax in cohorts 1 and 2. Plasma con-
centrations were plotted based on the midpoint of the sampling time
window for cohorts 2 to 4.
(ii) Population pharmacokinetic modeling. Using data from appro-
priate previous clinical studies in adults, a population PKmodel has been
developed to describe ceftazidime and avibactam exposure (29). Ceftazi-
dime and avibactam plasma concentrations, pediatric patient demo-
graphics, and disease status data from cohorts 1 to 4 of the present study
TABLE 2 Baseline patient characteristics (safety analysis population)
Parameter
Value for cohort:
1
(12 to18 yr)
(n 8)
2
(6 to12 yr)
(n 8)
3
(2 to6 yr)
(n 8)
4
(3 mo to2 yr)
(n 8)
Age, yr
Mean (SD) 14.9 (1.6) 8.0 (1.4) 3.5 (1.0) 0.9 (0.5)
Median (range) 14.9 (13.0–17.3) 7.7 (6.5–10.8) 3.8 (2.1–4.9) 0.9 (0.3–1.8)
Female, n (%) 5 (62.5) 3 (37.5) 6 (75.0) 3 (37.5)
Race, n (%)
White 6 (75.0) 6 (75.0) 7 (87.5) 5 (62.5)
Black or African American 1 (12.5) 2 (25.0) 0 3 (37.5)
Othera 1 (12.5) 0 1 (12.5) 0
Weight, kg; mean (SD) 51.90 (7.15) 24.95 (3.03) 15.73 (2.39) 9.20 (2.51)
BMI, kg/m2; mean (SD) 20.80 (3.21) 15.41 (0.78) 15.47 (0.95) NAd
CrCL, ml/min/1.73 m2; mean (SD) 115.29 (18.14) 156.97b (42.92) 181.57 (100.99) 104.35 (26.20)
Normal renal function, n (%) 8 (100) 8 (100) 8 (100) 8 (100)
Any concomitant antibiotic,c n (%) 8 (100) 8 (100) 8 (100) 8 (100)
Lincosamides 3 (37.5) 2 (25.0) 4 (50.0) 6 (75.0)
3rd-generation cephalosporins other than ceftazidime 1 (12.5) 3 (37.5) 1 (12.5) 1 (12.5)
Penicillins plus -lactamase inhibitors 1 (12.5) 0 2 (25.0) 2 (25.0)
Vancomycin 1 (12.5) 1 (12.5) 0 2 (25.0)
Metronidazole 2 (25.0) 2 (25.0) 0 0
Aminoglycosides 2 (25.0) 1 (12.5) 0 1 (12.5)
1st-generation cephalosporins 1 (12.5) 0 1 (12.5) 1 (12.5)
Azithromycin 1 (12.5) 1 (12.5) 1 (12.5) 0
Extended-spectrum penicillin 1 (12.5) 1 (12.5) 1 (12.5) 0
Meropenem 0 2 (25.0) 0 0
Levofloxacin 0 0 2 (25.0) 0
a Asian (n 1 in cohort 3 [2 to6 years]) and American Indian or Alaskan native (n 1 in cohort 1 [12 to18 years]).
b One patient in cohort 2 (6 to12 years) had a value greater than the upper limit of normal and is not included in the mean (SD) calculation.
c Taken any time between the initiation of study therapy and the day 3 follow-up assessment. Most commonly used antibiotics/groups are shown.
d NA, not applicable.
Bradley et al.
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were used to update this model (29, 42). From this updated model, indi-
vidual PK profiles for pediatric patients with available ceftazidime and
avibactam plasma concentration data were estimated using the empirical
Bayesian post hoc estimates. Ceftazidime and avibactam AUC0– values
for cohorts 3 and 4 were derived from these population PK modeled
profiles.
(iii) Safety. Safety and tolerability data were collected for each patient
from the time of informed consent from the parent(s) or other legally
acceptable representative(s) and informed assent from the patient, as ap-
propriate, from day 1 or day 1 through to the day 3 follow-up visit.
Safety and tolerability data were analyzed from time of first dose onward
and were based on adverse event (AE) and serious AE reports, vital sign
measurements (at baseline, at 2, 4, 6, and 12 h, and at 2 and 3 days after the
EOI), electrocardiograms (at baseline and 15 min after EOI), physical
examinations (at baseline and day 3), and clinical laboratory tests (at
baseline and day 3). The clinical significance of laboratory results was
determined by the investigator according to a predefined set of criteria.
AEs were listed and tabulated by system organ class (SOC) and preferred
term (PT) according to the Medical Dictionary for Regulatory Activities
(MedDRA), version 16.1.
Statistical analysis. The planned sample size was based on typical PK
characterization studies. No statistical calculations were performed to de-
termine sample size. A minimum target of 32 patients was set for all
cohorts collectively with at least 8 patients in each cohort. The PK analysis
population included all patients who had received an i.v. study dose of
ceftazidime-avibactam and had at least 1 postdose blood sample. An
evaluable patient was defined as a patient who provided PK blood samples
at50%of the sampling time points. PKparameters were summarized by
analyte and measurement time using descriptive statistics. All analyses
were performed using Statistical Analysis Software (SAS, release 9.1 or
higher) (SAS Institute, Inc., Cary, NC) or PhoenixWinNonlin version 6.2
or higher (Pharsight Corporation,MO). Population PKmodelingwas per-
formed using theNONMEM software (version 7.2; ICONDevelopment So-
lutions, Hanover, MD) running under PsN (Perl-speaks-NONMEM) 3.7.6
on a grid of CentOS 5.6 Linux servers, using the Intel Fortran compiler ver-
sion 12.0.4. The safety analysis population included all patients who had
received any amount of an i.v. study dose of ceftazidime-avibactam. No
statistical tests were performed for any safety analyses.
RESULTS
Patients. A total of 35 patients were enrolled across the 4 cohorts
at 11 centers in the U.S. Three patients who were enrolled into
cohort 1 did not receive any study medication (2 withdrew con-
sent and 1 was withdrawn due to failing eligibility criteria). No
patients were withdrawn due to AEs. Thirty-two patients (8 in
each cohort) received the full ceftazidime-avibactam dose and 31
patients completed the study. Study completionwas generally bal-
anced across the 4 cohorts. One patient in cohort 2 did not attend
the day 3 visit, and no follow-up data are available for this patient.
Both the PKpopulation and safety population comprised a total of
32 patients. Patient baseline demographic and clinical character-
istics are summarized in Table 2. Excluding age, BMI, and CrCL,
all patient baseline characteristics were similar across the 4 co-
horts. Patients were predominantly white (n  24), and all had
normal renal function at baseline. There was a higher proportion
of female patients in cohorts 1 and 3 and a higher proportion of
male patients in cohorts 2 and 4.
The most frequent current infections were cellulitis
(15.6%), limb abscess (9.4%), and appendicitis (9.4%). All pa-
tients had received at least 1 prior antibiotic medication (data
not shown) and received at least 1 concomitant antibiotic med-
ication (Table 2). Overall, the most common antibiotic medi-
cations received were clindamycin (lincosamide) and third-
generation cephalosporins (prior, 34.4% for both; concomitant,
46.9% and 18.8%, respectively). Of the 32 children enrolled in the
study, 4 received concurrent vancomycin and 4 received an ami-
noglycoside.
Pharmacokinetics. Mean (SD) plasma concentration-time
curves from the available data for ceftazidime and avibactam fol-
lowing single-dose administrations on day 1 were similar across
cohorts 1 to 4 for both drugs (Fig. 1 and 2); due to sparse sampling
of cohorts 3 and 4, the midpoints were used to plot the data to
enable comparison between all cohorts. Geometricmean (percent
coefficient of variation) Cmax was similar across all four age co-
horts for ceftazidime and avibactam (Table 3). Due to the sparse
sampling, Cmax was the only parameter measured for cohorts 3
(2 to6 years) and 4 (3months to2 years).Median (range)
time tomaximumplasma concentration (tmax) for cohorts 1 and 2
was similar and occurred immediately after EOI. The geometric
mean AUC0–t and AUC0– were similar between cohorts 1 and 2
for both ceftazidime and avibactam. For both cohorts, the geo-
metric mean value of AUC0–t was approximately 99% of the
AUC0–. Median (range) terminal t1/2 values for ceftazidime were
similar between cohorts 1 and 2, 1.7 h (0.9 to 2.8) and 1.6 h (0.9 to
1.8), respectively. The geometricmeanweight-normalizedCLwas
slightly higher in cohort 2 than in cohort 1 (CL, 0.226 versus 0.169
liter/kg/h), whileVss was lower in cohort 2 than cohort 1 (Vss, 13.0
versus 22.2 liters), although there was large within-cohort vari-
ability and CL was considered broadly comparable between co-
horts (Table 3). Similar findings were also observed in cohort 1
and cohort 2 formedian avibactam t1/2 (range) values of 1.6 h (0.9
FIG 1 Arithmetic mean (SD) plasma concentration-time curves for cefta-
zidime for cohorts 1 to 4 following single-dose (day 1) administration of cef-
tazidime-avibactam (pharmacokinetic analysis population).
Ceftazidime-Avibactam Pediatric Pharmacokinetics
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to 2.8) and 1.7 h (0.9 to 2.0), respectively, and geometric mean CL
and Vss values (t1/2, 1.6 versus 1.7 h; CL, 13.7 versus 8.9 liters/h;
Vss, 31.0 versus 19.3 liters). Like ceftazidime, geometric mean
weight-normalized CL for avibactam differed between cohorts 1
and 2, with large within-cohort variability, but was considered
broadly similar between cohorts (Table 3).
Population pharmacokinetic modeling. The final population
PKmodels for ceftazidime and avibactamwere two-compartment
disposition models with first-order elimination from the central
compartment, including the covariate effect of the allometric
model for body weight and the age effect on renal maturation.
Goodness-of-fit plots and visual predictive checks indicated that
the population PKmodels accommodated the pediatric data well,
with no obvious bias, and were considered sufficiently robust to
support extrapolation to younger children for use in PTA simula-
tions (42). AUC0– values were estimated from population PK
modeling; they were comparable across all 4 cohorts and in line
with adult exposures (Table 4).
Safety. A summary of AEs is shown in Table 5. Overall, 6
patients (18.8%) reported a total of 9 AEs with onset after the
start of the infusion of ceftazidime-avibactam. No AEs were
reported in cohort 1 or cohort 2. Four patients (50%) reported
at least 1 AE in cohort 3; 2 patients (25%) reported at least 1 AE
in cohort 4. All AEs were of mild or moderate intensity. The
most common AEs reported were gastrointestinal, occurring in
3 (9.4%) patients. Only 1 AE was reported that was considered
related to the study drug: sinus tachycardia in a 14-month-old
male patient in cohort 4. The patient entered the study with
medical conditions including cervical lymphadenitis, wound
infection (staphylococcal), and fever but no history of cardio-
vascular conditions. The event was of mild intensity, began
approximately 1 h after the start of the ceftazidime-avibactam
infusion, and lasted approximately 0.5 days. After a full review
of this case, no new safety concerns were identified. No deaths
or serious AEs were reported in the study.
No potentially clinically significant hematology, clinical chem-
istry, or liver function tests were reported, and there were no clin-
FIG 2 Arithmetic mean (SD) plasma concentration-time curves for avibac-
tam for cohorts 1 to 4 following single-dose (day 1) administration of ceftazi-
dime-avibactam (pharmacokinetic analysis population).
TABLE 3 Summary of ceftazidime and avibactam pharmacokinetic parameters measured in pediatric patients (pharmacokinetic population)
Drug and parametera
Value for cohort:
1 (n 8)
(12 to18 yr)
2 (n 8)
(6 to12 yr)
3 (n 8)
(2 to6 yr)
4 (n 8)
(3 mo to2 yr)
Ceftazidime
Cmax (mg/liter) 79.8 (41.8) 81.3 (17.8) 80.1
b (14.7) 91.7b (19.6)
tmax
c (h) 2.0 (1.9–2.6) 2.1 (1.9–2.4)
AUC0–t (h · mg/liter) 229.2 (30.9) 217.8 (18.4)
AUC0– (h · mg/liter) 230.6 (30.7) 221.2 (17.4)
t1/2
c (h) 1.7 (0.9–2.8) 1.6 (0.9–1.8)
Vss (liters) 22.2 (42.0) 13.0 (17.8)
CL (liter/h) 8.7 (45.5) 5.6 (16.0)
CL/W (liter/kg/h) 0.169 (37.9) 0.226 (20.0)
Avibactam
Cmax (mg/liter) 15.1 (52.4) 14.1 (23.0) 13.7
b (22.4) 16.3b (22.6)
tmax (h) 2.0 (1.9–2.6) 2.1 (1.9–2.4)
AUC0–t (h · mg/liter) 36.3 (33.7) 34.4 (23.4)
AUC0– (h · mg/liter) 36.4 (33.6) 34.8 (22.6)
t1/2 (h) 1.6 (0.9–2.8) 1.7 (0.9–2.0)
Vss (liters) 31.0 (53.3) 19.3 (27.0)
CL (liter/h) 13.7 (52.6) 8.9 (30.2)
CL/W (liter/kg/h) 0.267 (44.2) 0.359 (35.8)
a Values are geometric mean (coefficient of variation [%]) unless stated otherwise. CL/W, weighted clearance or clearance by body weight.
b Plasma concentration as measured at end of infusion.
c Median (range).
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ically significant changes in electrocardiograms as determined by
the study investigators.
DISCUSSION
This phase I trial was the first study to evaluate the PK profile,
safety, and tolerability of a single dose of ceftazidime-avibactam in
hospitalized pediatric patients. The study allowed successful char-
acterization of the single-dose PK profile of ceftazidime and
avibactam in a pediatric population aged from 3 months to 18
years who were already receiving systemic antibiotic therapy for
suspected or confirmed infection.
Ceftazidime and avibactam plasma PK parameters of Cmax,
AUC0–t, AUC0–, tmax, and t1/2 were similar between cohort 1
(12 to 18 years) and cohort 2 (6 to 12 years) for both
drugs. Ceftazidime and avibactam plasma concentration profiles
were similar in cohorts 1 and 2 across the sampling time points.
Based on the sparse blood sampling and overlay of available
plasma concentration data against time for the 4 cohorts, observed
mean plasma concentrations appeared similar in cohorts 3 (2
to6 years) and 4 (3 months to2 years) to those observed in
cohorts 1 and 2.
The PK profiles of single-dose ceftazidime and avibactam in
this hospitalized pediatric population were similar to those previ-
ously observed in an adult population. In a phase I study in healthy
adults (44), geometric mean Cmax and total exposures (AUC0–)
following a single 2-h i.v. infusion of ceftazidime-avibactam at
2,000 mg/500 mg were 88.1 mg/liter and 289 mg · h/liter, respec-
tively, for ceftazidime and 15.2 mg/liter and 42.1 mg · h/liter, re-
spectively, for avibactam. In the current study, peak exposure
(Cmax) of both ceftazidime and avibactam in cohorts 1 and 2 was
comparable to that previously described for the adult population;
however, total exposures were somewhat lower than those for the
adult population (approximately 40 mg · h/liter lower for ceftazi-
dime and approximately 4.5mg · h/liter lower for avibactamwhen
comparing cohorts 1 and 2 to adults).
Due to the sparse sampling in cohorts 3 and 4, population PK
modeling was used to estimate AUC0– to enable comparison
TABLE 4 Summary of ceftazidime and avibactam observed and population pharmacokinetic model-predicted exposures in pediatric patients
(pharmacokinetic population)
Drug
AUC0- (h · mg/liter)
Observed value for cohorta: Predicted value for cohortb:
Value for adult reference
populationc (n 16)1 (12 to18 yr) 2 (6 to12 yr) 3 (2 to6 yr) 4 (3 mo to2 yr)
Ceftazidime 230.6 (30.7) 221.2 (17.4) 255.32 (43.95) 286.27 (37.13) 289.0d (15.4)
Avibactam 36.4 (33.6) 34.8 (22.6) 43.25 (12.14) 48.99 (10.64) 42.1e (16.0)
a Data for cohorts 1 and 2 are geometric means (percent coefficients of variation).
b Data for cohorts 3 and 4 are means (SD) based on population pharmacokinetic model predictions (42).
c Values are geometric means (percent coefficients of variation) for observed exposures from a phase I study in healthy adult volunteers on day 1 after receiving a single dose of
ceftazidime-avibactam (2,000 to 500 mg) (44).
d n 15.
e n 13.
TABLE 5 Summary of AEs in cohorts 3 and 4 (safety analysis population)c
System organ class/preferred term
No. (%) of patients with AE for cohortb:
3 (2 to6 yr)
(n 8)
4 (3 mo to2 yr)
(n 8)
Totala
(n 32)
Any 4 (50.0) 2 (25.0) 6 (18.8)
Cardiac disorders 0 1 (12.5) 1 (3.1)
Sinus tachycardia 0 1 (12.5) 1 (3.1)
Gastrointestinal disorders 3 (37.5) 0 3 (9.4)
Constipation 1 (12.5) 0 1 (3.1)
Diarrhea 1 (12.5) 0 1 (3.1)
Vomiting 1 (12.5) 0 1 (3.1)
Investigations 1 (12.5) 0 1 (3.1)
Increased alanine aminotransferase 1 (12.5) 0 1 (3.1)
Increased aspartate aminotransferase 1 (12.5) 0 1 (3.1)
Increased blood triglycerides 1 (12.5) 0 1 (3.1)
Increased gamma-glutamyltransferase 1 (12.5) 0 1 (3.1)
Injury, poisoning, and procedural complications 0 1 (12.5) 1 (3.1)
Procedural site reaction 0 1 (12.5) 1 (3.1)
a Total patient number includes cohorts 1 to 4.
b Onset on or after the date and time of the first dose of ceftazidime-avibactam and up to and including the day 3 follow-up visit.
c No AEs were reported in cohorts 1 and 2.
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across all cohorts. The population modeling provided a good es-
timate of study drug exposure, with simulated study drug expo-
sures (AUC) similar across all four age cohorts for avibactam and
ceftazidime and broadly comparable with previously observed
data in adults.
This study did not identify any new safety concerns, and the
data supported the decision to initiate multiple-dose phase II
treatment studies investigating the safety of ceftazidime-avibac-
tam in hospitalized pediatric patients with cIAI (NCT02475733)
or cUTI (NCT02497781). Further PK/PDmodeling has been com-
pleted using the PK data generated in the present study and will be
described separately. This compares modeled exposures in pediatric
patients to those in adults and predicts PTA against the preclinical
targets associated with efficacy in adults. Together, these data have
been used to informdose selection for the planned phase II studies of
ceftazidime-avibactam in pediatric patients.
Conclusions. The data from this study were sufficient to char-
acterize the PK profile of ceftazidime and avibactam in pediatric
patients hospitalized with infection who received a single-dose i.v.
infusion of ceftazidime-avibactam. PK profiles of both study
drugs were comparable across all 4 age cohorts and were broadly
similar to those previously observed in adults. No new safety con-
cerns were identified. In addition, these data support the progres-
sion to phase II trials of ceftazidime-avibactam in pediatric pa-
tients and have been instrumental in the development of
population PKmodeling and subsequent PTA simulation that has
supported dose decisions in these phase II studies.
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